If you want to support independent women's media, become a Mamamia subscriber . Get an all-access pass to everything we make, ...
SHELTON, CT / ACCESS Newswire / October 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...
Morning Overview on MSN
A new antiviral is cleared for herpes sores that standard drugs failed to heal in immunocompromised adults
Pritelivir, sold as Hovilpri, won U.S. approval on October 9, 2026 for one narrow job: clearing mucocutaneous herpes simplex ...
Can you give me information about laryngopharyngeal reflux? I develop a croaky voice at times and have lots of mucus in the ...
A new PLOS Pathogens study shows that the interferon-induced GTPase GBP7 unexpectedly promotes HSV-1 infection by activating ...
The US Food and Drug Administration (FDA) has approved Hovilpri (pritelivir) tablets for immunocompromised adults battling ...
Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off ...
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
Herpes Awareness Day takes place annually on Oct. 13. The day promotes awareness and aims to end the stigma surrounding the herpes simplex virus, commonly known as herpes.
The United States Food and Drug Administration (FDA) granted approval on October 9, 2026, for Hovilpri (pritelivir), a tablet ...
The FDA approved Hovilpri for herpes lesions that do not respond to other antivirals in immunocompromised adults. In a trial, 63% achieved complete healing.
The FDA has approved pritelivir to treat mucocutaneous lesions caused by herpes simplex virus in immunocompromised adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results